Literature DB >> 11805006

Serum paraoxonase activity: a new additional test for the improved evaluation of chronic liver damage.

Natàlia Ferré1, Jordi Camps, Eduard Prats, Elisabet Vilella, Antoni Paul, Lídia Figuera, Jorge Joven.   

Abstract

BACKGROUND: Paraoxonase 1 (PON1) is an ester hydrolase present in serum and in the liver. The aims of the present study were to investigate the following: (a) the relationship between serum PON1 activity alterations and the degree of liver damage in patients with chronic liver disease; (b) the influence of genetic variability on serum PON1 activity; and (c) the efficacy of serum PON1 activity measurement, alone and in combination with standard liver function tests, in the assessment of liver damage.
METHODS: We studied 68 patients with liver cirrhosis, 107 patients with chronic hepatitis, and 368 apparently healthy volunteers. Baseline and salt-stimulated PON1 activities were measured by the hydrolysis of paraoxon. PON1 genotyping at positions 55 and 192 was analyzed by PCR and restriction isotyping.
RESULTS: Baseline and stimulated PON1 activities were decreased (P <0.001) in chronic hepatitis and in liver cirrhosis. PON1 activity was significantly correlated with serum total proteins, albumin, and bilirubin in patients but not in controls. There were no significant differences with respect to allele and genotype frequencies between patients and controls. The combination of baseline serum PON1 with five standard biochemical tests had a higher classification accuracy (94% of patients; 96% of controls) than the five standard tests alone (75% of patients; 96% of controls). ROC plots demonstrated a high diagnostic accuracy for baseline serum PON1 [area under the curve, 0.89 (95% confidence interval, 0.86-0.93) in chronic hepatitis and 0.96 (95% confidence interval, 0.94-0.99) in cirrhosis]. Baseline PON1 provided the highest ROC area for cirrhosis vs controls.
CONCLUSIONS: The significant decrease of PON1 activity in chronic liver diseases is related to the degree of hepatic dysfunction and not to allelic or genotypic differences. Addition of serum PON1 activity measurement to the current battery of tests may improve the evaluation of chronic liver diseases.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11805006

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  39 in total

1.  The role of 'paraoxonase-1 activity' as an antioxidant in coronary artery diseases.

Authors:  Maharudra Shekhanawar; Sarala M Shekhanawar; D Krisnaswamy; V Indumati; D Satishkumar; V Vijay; T Rajeshwari; M Amareshwar
Journal:  J Clin Diagn Res       Date:  2013-07-01

2.  Serum arylesterase and paraoxonase activity in patients with chronic hepatitis.

Authors:  Suleyman Sirri Kilic; Suleyman Aydin; Nermin Kilic; Fazilet Erman; Suna Aydin; Ilhami Celik
Journal:  World J Gastroenterol       Date:  2005-12-14       Impact factor: 5.742

3.  Correlation of serum arylesterase activity on phenylacetate estimated by the integrated method to common classical biochemical indexes of liver damage.

Authors:  Fei Liao; Xiao-yun Zhu; Yong-mei Wang; Yun-sheng Zhao; Lian-ping Zhu; Yu-ping Zuo
Journal:  J Zhejiang Univ Sci B       Date:  2007-04       Impact factor: 3.066

Review 4.  Chemokine ligand 2 and paraoxonase-1 in non-alcoholic fatty liver disease: The search for alternative causative factors.

Authors:  Jordi Camps; Jorge Joven
Journal:  World J Gastroenterol       Date:  2015-03-14       Impact factor: 5.742

5.  Time-dependent modulation of rat serum paraoxonase 1 activity by fasting.

Authors:  Elena Thomàs-Moyà; Antònia Nadal-Casellas; Magdalena Gianotti; Isabel Lladó; Ana María Proenza
Journal:  Pflugers Arch       Date:  2006-12-05       Impact factor: 3.657

6.  Effects of amlodipine, captopril, and bezafibrate on oxidative milieu in rats with fatty liver.

Authors:  Zvi Ackerman; Mor Oron-Herman; Talma Rosenthal; Orit Pappo; Gabriela Link; Ben-Ami Sela; Maria Grozovski
Journal:  Dig Dis Sci       Date:  2007-08-22       Impact factor: 3.199

7.  Decreased paraoxonase-1 activity is associated with alterations of high-density lipoprotein particles in chronic liver impairment.

Authors:  Judit Marsillach; Gerard Aragonès; Bharti Mackness; Michael Mackness; Anna Rull; Raúl Beltrán-Debón; Juan Pedro-Botet; Carlos Alonso-Villaverde; Jorge Joven; Jordi Camps
Journal:  Lipids Health Dis       Date:  2010-05-14       Impact factor: 3.876

8.  Paraoxonase-1 status in patients with hereditary hemochromatosis.

Authors:  Nicola Martinelli; Anabel García-Heredia; Helena Roca; Núria Aranda; Victoria Arija; Bharti Mackness; Michael Mackness; Fabiana Busti; Gerard Aragonès; Juan Pedro-Botet; Federica Pedica; Ivana Cataldo; Judit Marsillach; Jorge Joven; Domenico Girelli; Jordi Camps
Journal:  J Lipid Res       Date:  2013-03-06       Impact factor: 5.922

9.  Serum lactonase and arylesterase activities in alcoholic hepatitis and hepatitis B.

Authors:  Mukund Ramchandra Mogarekar; Swati Jitendra Talekar
Journal:  Indian J Gastroenterol       Date:  2013-05-23

10.  Effects of vitamin A, C and E, or omega-3 fatty acid supplementation on the level of paraoxonase and arylesterase activity in streptozotocin-induced diabetic rats: an investigation of activities in plasma, and heart and liver homogenates.

Authors:  Mahnaz Zarei; Shima Fakher; Seyed Mohammad Bagher Tabei; Mohammad Hassan Javanbakht; Hoda Derakhshanian; Payam Farahbakhsh-Farsi; Mohammad Reza Sadeghi; Ebrahim Mostafavi; Mahmoud Djalali
Journal:  Singapore Med J       Date:  2016-03       Impact factor: 1.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.